William C. Kuzell, M.D.; Ralph W. Schaffarzick, M.D.; Beverly Brown, M.S.; Eldon A. Mankle, B.A.
JAMA. 1952;149(8):729-734. doi:10.1001/jama.1952.02930250011004.
Text Size: A A A
Published online

Phenylbutazone (butazolidin®) is one of a group of pyrazole derivatives developed by the chemists of the J. R. Geigy Co., of Basel, Switzerland, in an attempt to find compounds with pharmacologie properties similar to aminopyrine but without its toxicity (see accompanying figure). Many clinical trials have been conducted in Switzerland and Germany, with a combination of aminopyrine and phenylbutazone in equal parts (the mixture is known as irgapyrin® in Europe and butapyrin® in this country.1) These studies were initiated since phenylbutazone was found to promote the solubility of the relatively insoluble aminopyrine, thus permitting its parenteral use. There have been no reports of extensive clinical trials of phenylbutazone alone, whereas the clinical effects and toxicity of aminopyrine are well known. Since the antirheumatic properties of the mixture have been so favorable, it was desirable to evaluate phenylbutazone separately.

Considerable pharmacologic investigation has been reported. Wilhelmi1a demonstrated that phenylbutazone


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.